2025 파트너사
2025 合作伙伴
2025 パートナー
Lead Partner
Abzena
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products through to clinical development. Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena.
Senior Partners
BSP Pharmaceuticals
BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a strategic interest in specific therapeutic areas.
The facility is designed to handle conventional small molecules, Biologics and ADCs (from Conjugation to Fill Finish) and very much focused on innovative compounds.
With full containment equipment, applying the most advanced and safe technologies, BSP can offer a wide range of services for Pre-Clinical, Clinical and Commercial supply in compliance with the highest Quality requirements.
Ensuring supply security for these life-saving product categories is the basis of the strategic partnerships that BSP has established to date.
Cytiva
Cytiva, now with the life sciences business from Pall Corporation, is a global biotechnology leader dedicated to helping customers discover and commercialize the next generation of therapeutics. We bring dedicated technical expertise and a broad portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients.
WuXi XDC
WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.
Ajinomoto Pharma Services
Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, they provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on.
Synaffix
Synaffix is a biotech company with a clinical-stage platform technology that enables best-in-class antibody-drug conjugates (ADCs), bispecific antibodies and other targeted therapeutics under a technology outlicensing business model. Synaffix was fully acquired by Lonza in June 2023. Aimed at enabling innovative medicines for patients in areas of high unmet medical need, Synaffix has forged a growing number of collaborations with top tier biotech and pharma companies by enabling best-in-class therapeutic candidates for their pipelines. Centered entirely around the antibody glycan, Synaffix has established a simple, rapidly deployable technology platform, enabling any company with an antibody to develop a proprietary, best-in-class ADC or bispecific.
Program Partner
LigaChem Biosciences
Shanghai Lide Biotech
LIDE is an award winning preclinical oncology CRO offering novel in-vivo options to validate ADCs with fresh patient samples, as well as faster studies using our proprietary MiniPDX and IO-FIVE assays. We also offer traditional services like 2D and 3D in-vitro assays, 2200 in-vivo PDX models covering 50 indications, CDX models, conditionally reprogrammed cell lines, and immuno-oncology studies with syngeneic or humanized mice.
Joinn Laboratories
Exhibition Partners
Axplora
Axplora, created from the merger of Farmabios, Novasep and PharmaZell, is a leading API manufacturing partner to the world's leading pharmaceutical and
biotechnology companies, delivering top quality active ingredients on time and at scale, to the highest industry standards. Axplora is dedicated to helping pharmaceutical companies make critical medicines better, faster, safely, reliably, and sustainably benefitting patients worldwide.
The group provides unique services for the development, fast-track, clinical supply and commercial cGMP manufacture of ADCs including the payload-linker and the bioconjugation, leveraging its in-house purification expertise, HPAPI culture & state-of-the art cGMP conjugation facilities. We offer a full and flexible range of ADC manufacturing services with hand-run experience on different conjugation platforms.
Asymbio
AsymBio is committed to be a technology-driven CDMO with a global vision and best-in-class solutions for bioconjugates, antibodies, etc. We are capable of delivering bioconjugate IND projects in 13 months and BLA projects in 24 months. AsymBio is the innovative, reliable and client centric CDMO partner driven for your success in the competitive pharmaceutical landscape.
Bruker Cellular Analysis
At Bruker Cellular Analysis, our mission is to transform live single cell biology research through cutting-edge, science-driven technologies that enable researchers to study cellular function and molecular mechanisms with unmatched precision and insight. By integrating advanced optofluidics, live single-cell imaging, functional cell biology, and multiomic data, we unravel complex biology to accelerate critical scientific discoveries and therapeutic innovations.
www.brukercellularanalysis.com
PROVEO
Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete supply chain solution for Antibody Drug Conjugates (ADCs). Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.
Biointron
Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.
Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 2,000 biotech and pharma companies worldwide. Contact us: +1(732)790-8340, or info@biointron.com.
Piramal
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide.
Veranova
Veranova is a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients for pharma and biotech customers. Veranova’s global team of highly skilled process chemists and analytical scientists possess over a decade of experience developing and scaling up processes for linking small molecule payloads to polymers in support of antibody-drug conjugates and polymer drug conjugates.
Charles River Laboratories
Founded in 1947, Charles River Laboratories is the leading global drug development partner. Over the past 5 years, Charles River has supported the research and development of over 80% of the new drugs approved by the FDA.
• Biologics Testing Solutions
With 50+ years of experience and over 40,000 tests run annually at the GMP biologics testing facilities, we provide comprehensive testing services for a wide range of modalities.
• Cell and Gene Therapy CDMO
We have supported the development of 20 FDA-approved cell and gene therapies and have conducted more than 1,000 studies in this field over the past year.
OmniAb
OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, is used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions.
Biocytogen
Biocytogen (HKEX: 02315) is a global biotech company advancing antibody-based drug discovery with innovative gene-editing technology. Its proprietary RenMice® platforms enable fully human monoclonal, bispecific, and nanobody discovery. Through RenBiologics™, Biocytogen offers a library of over 1 million human antibody sequences for global collaboration.Its BioMice® brand provides a few thousand off-the-shelf animal and cell models, along with preclinical pharmacology and gene-editing services for clients worldwide.
Nona Biosciences
Branding Partner
CARBOGEN AMCIS
CARBOGEN AMCIS provides drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. Our capabilities span from contract chemical process research and development to the supply of Active Pharmaceutical Ingredients (APIs) - as well as drug products for preclinical studies, clinical trials and commercial use. Besides being a service provider we also offer high quality Cholesterol and Vitamin D analog products. We aim to manufacture pharmaceutical ingredients at the highest standard of GMP whilst protecting the environment.
